RT Journal Article
T1 FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma.
A1 Cabrejos, Sheila
A1 Moreira, Ana
A1 Ramirez, Andreina
A1 Quirce, Santiago
A1 Soto-Campos, Gregorio
A1 Davila, Ignacio
A1 Campo, Paloma
K1 IgE
K1 Allergy
K1 Asthma
K1 Exacerbations
K1 Omalizumab
K1 Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
AB A Spanish real-world study in patients with severe persistent asthma who achieved asthma control after a one-year treatment with omalizumab highlighted the phenotypic heterogeneity of these patients (FENOMA study). In this subanalysis, we describe the clinical improvement in patients with severe allergic asthma in this study (positive skin test and IgE level 30-1500 IU/mL); n=240. FENOMA was an observational, multicentre, retrospective study in 345 patients achieving asthma control according to Spanish guidelines (GEMA). Baseline demographic and asthma-related characteristics were collected. Outcomes analyzed were those included in asthma control definition plus changes in background treatments and in blood eosinophil count (%) and exhaled nitric oxide fraction [FeNO]. At baseline, patients were aged 45.4±15.0 years; 67% were women. Median (Q1;Q3) IgE levels were 302.5 (154.0; 553.5) IU/mL. After one-year treatment with omalizumab: 43.3% of patients had daytime symptoms vs 97.7% before treatment and 49.6% stopped taking oral corticosteroids. FEV1 increased a median of 12.0 (4.0; 23.0)%; P  This study highlights the asthma control achieved by patients with severe allergic asthma treated with omalizumab, with relevant benefits on the burden of the disease both on patients and the healthcare system.
PB Dove Press
SN 1178-6965
YR 2020
FD 2020-05-06
LK http://hdl.handle.net/10668/15615
UL http://hdl.handle.net/10668/15615
LA en
NO Cabrejos S, Moreira A, Ramirez A, Quirce S, Soto Campos G, Dávila I, et al. FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma. J Asthma Allergy. 2020 May 6;13:159-166
DS RISalud
RD Apr 5, 2025